Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

quizartinib dihydrochloride

View Patient Information
The dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AC010220 2HCl
N-(5-tert-butyl-isoxazol-3-yl)-N'-(4-(7-(2-morpholin-4-ylethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea dihydrochloride
US brand name:Vanflyta
Code name:AC220 2HCl
Chemical structure:urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N'-(4-(7-(2-(4-morpholinyl) ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)-, hydrochloride (1:2)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search